The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Pandion Shares Trade Up 134% on $1.85 Billion Acquisition by Merck

  ()
Pandion Therapeutics shares reached a new 52-week high after the company reported it agreed to be acquired by pharmaceutical giant Merck & Co. in an all cash transaction for $60 per share. read more >

Nektar Therapeutics Planning Phase 2/3 Studies with Merck and SFJ Pharma for Head and Neck Cancer

  ()
Nektar Therapeutics shares traded 14% higher after the company reported it plans to conduct a Phase 2/3 study of bempegaldesleukin in combination with Merck's KEYTRUDA® in patients with squamous cell carcinoma of the head and neck and is partnering on a second Phase 2/3 study with SFJ Pharmaceuticals that will provide $150 million to fund development. read more >
News Update

Pharma Developer Contemplates Adding Lung Scarring as Key Endpoint in Phase 2b/3 COVID-19 Trial

News Update
  ()
Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol. read more >

ImmunoGen Shares Rise 30% After Firm Reports FY20 Earnings and 2021 Outlook

  ()
Shares of ImmunoGen Inc. reached a new 52-week high after the company announced Q4/20 and FY/20 business operating and financial results. read more >

AC Immune Reports 'Positive Interim Results' from Novel Phase 1b/2a Alzheimer's Vaccine Trial

  ()
Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer's trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer's disease. read more >
News Update

Pharmaceutical Developer Hires Laboratory to Conduct Preclinical Studies of Psychedelic Compound DMT

News Update
  ()
Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients. read more >

Drug Repurposer Ventures into New Area, Use of Psychedelic in Stroke

Research Report
  ()
This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report. read more >

Coverage Initiated on Firm Developing Gold Nanoparticle Therapy for Neurological Diseases

Research Report
  ()
The reasons Clene is a compelling investment are outlined in a ROTH Capital Partners report. read more >

Small-Cap Psychedelic Wellness Company Makes First Acquisition: Ketamine Infusion Centers

  ()
DELIC aims to become a leader in psychedelic health and wellness clinics. read more >
News Update

Neurosciences Firm Provides Insight on Recent Alzheimer's/Amyloid Field Developments

News Update
  ()
ProMIS Neurosciences offered its perspective on the latest progress in the Alzheimer's/Amyloid field. The firm stated that two recent positive events support the case for PMN310 to be considered "best in class." read more >

GW Pharmaceuticals Shares Gain 46% on $7.2 Billion Acquisition by Jazz Pharmaceuticals

  ()
Shares of GW Pharmaceuticals reached a new 52-week high after the company reported it agreed to be acquired by Jazz Pharmaceuticals in a combination cash and stock deal for $220.00 per share. read more >

Cassava Shares Triple After Interim Trial Data Shows Simufilam Improves Cognition and Behavior in Alzheimer's Disease

  ()
Shares of Cassava Sciences traded 207% higher after the firm provided an interim analysis from an ongoing study demonstrating that simufilam improves cognition and behavior in mild-to-moderate Alzheimer's disease patients. read more >

Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics

  ()
Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share. read more >

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT, the 'Spirit Molecule'

  ()
Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that it has established a clinical research program for the treatment of stroke focused on AP-188 (DMT), a known psychedelic compound. Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021. read more >

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness

  ()
Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial. read more >

Coverage Initiated on Biotech 'Improving Drugs Via Prodrug'

Research Report
  ()
KemPharm's key near-term catalyst, lead value driver and other pipeline drug candidates are discussed in a ROTH Capital Partners report. read more >

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial

  ()
Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients. read more >

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data

  ()
Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen. read more >

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug

  ()
Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis. read more >

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients

  ()
AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. read more >
News Update

Biotech Given Go-Ahead to Proceed with Phase 3 COVID-19 Study

News Update
  ()
Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2. read more >

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine

  ()
Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2. read more >

Aclaris Shares Triple in Value on Positive Topline Data from Phase 2a Rheumatoid Arthritis Trial

  ()
Shares of Aclaris Therapeutics Inc. soared to a new 52-week high after the company reported positive preliminary topline data from its Phase 2a trial of oral ATI-450 for moderate to severe rheumatoid arthritis. read more >
News Update

Life Sciences Firm Partners with University to Develop Biosynthetic Psilocybin

News Update
  ()
Revive Therapeutics entered into a research agreement with North Carolina State University to develop psilocybin utilizing a natural biosynthesis enzymatic platform. read more >
News Update

Neurosciences Firm Outlines Strategic Priorities for 2021

News Update
  ()
ProMIS Neurosciences discusses its four priority areas in 2021. read more >
Showing Results: 1 to 25 of 118 Next

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe